| pubmed-article:10825148 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10825148 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:10825148 | lifeskim:mentions | umls-concept:C0149925 | lld:lifeskim |
| pubmed-article:10825148 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:10825148 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:10825148 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:10825148 | lifeskim:mentions | umls-concept:C0015272 | lld:lifeskim |
| pubmed-article:10825148 | lifeskim:mentions | umls-concept:C1704243 | lld:lifeskim |
| pubmed-article:10825148 | lifeskim:mentions | umls-concept:C0044549 | lld:lifeskim |
| pubmed-article:10825148 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:10825148 | lifeskim:mentions | umls-concept:C0250417 | lld:lifeskim |
| pubmed-article:10825148 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:10825148 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:10825148 | pubmed:dateCreated | 2000-6-13 | lld:pubmed |
| pubmed-article:10825148 | pubmed:abstractText | Aberrant signal transduction pathways involved in the development of metastatic disease are poorly defined in both small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). Neuropeptide-driven positive feedback loops stimulating cell proliferation are characteristic of SCLC. The activation of phospholipase C (PLC)-beta1 is an early and common response to stimulation of G protein-coupled receptors by these neuroendocrine growth factors. The importance of PLC-beta in neuropeptide signaling prompted us to compare PLC-beta isoform expression and activity in four independent SCLC cell lines and four independent NSCLC cell lines. We found that PLC-beta1 is more highly expressed in SCLC than in NSCLC, as indicated by Western blotting of cell lysates. All SCLC lines studied express PLC-beta1; only one of the NSCLC lines investigated showed detectable levels of the enzyme. NSCLC lines are significantly more sensitive to the antiproliferative effects of ET-18-OCH3 (edelfosine) compared with the SCLC lines, as indicated by [3H]thymidine uptake. The only SCLC cell line (NCI-H345) that is as sensitive as the NSCLC cell lines to ET-18-OCH3 also expresses uniquely low levels of PLC-beta1. The participation of PLC-beta1 in signaling by SCLC growth factor receptors is indicated by our finding that PLC-beta1 (but not PLC-beta3) coimnunoprecipitates with G(alpha)q/11 upon activation of neurotensin receptors; this association is inhibited by ET-18-OCH3. Ca2+ mobilization mediated by neurotensin receptors is also inhibited by ET-18-OCH3. The binding of GTPgammaS to G(alpha)q/11 upon treatment of SCLC cells with neurotensin is not inhibited by ET-18-OCH3. These findings indicate that ET-18-OCH3 does not interfere with G(alpha)q/11 activation but rather inhibits the association of G(alpha)q/11 with PLC-beta1. Our data suggest that PLC-beta is an important mediator of both SCLC and NSCLC proliferation. Differences in PLC-beta1 expression may be exploitable in the development of effective diagnostic and therapeutic tools. | lld:pubmed |
| pubmed-article:10825148 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10825148 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10825148 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10825148 | pubmed:month | May | lld:pubmed |
| pubmed-article:10825148 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:10825148 | pubmed:author | pubmed-author:WilliamsC LCL | lld:pubmed |
| pubmed-article:10825148 | pubmed:author | pubmed-author:ShaferS HSH | lld:pubmed |
| pubmed-article:10825148 | pubmed:author | pubmed-author:StrassheimDD | lld:pubmed |
| pubmed-article:10825148 | pubmed:author | pubmed-author:PhelpsS HSH | lld:pubmed |
| pubmed-article:10825148 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10825148 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:10825148 | pubmed:volume | 60 | lld:pubmed |
| pubmed-article:10825148 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10825148 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10825148 | pubmed:pagination | 2730-6 | lld:pubmed |
| pubmed-article:10825148 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:meshHeading | pubmed-meshheading:10825148... | lld:pubmed |
| pubmed-article:10825148 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10825148 | pubmed:articleTitle | Small cell lung carcinoma exhibits greater phospholipase C-beta1 expression and edelfosine resistance compared with non-small cell lung carcinoma. | lld:pubmed |
| pubmed-article:10825148 | pubmed:affiliation | Molecular Pharmacology Laboratory, Guthrie Research Institute, Syre, Pennsylvania 18840, USA. | lld:pubmed |
| pubmed-article:10825148 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10825148 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10825148 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10825148 | lld:pubmed |
